@midgardfinance.com🇺🇸 $LLY #Onswik and 🇩🇰 $NOVO #Awiqli are racing for the flat half of the business. Novo's insulin: EUR 1.7bn a quarter, flat since 2020. Incretins: Novo EUR 8.0bn, Lilly EUR 13.8bn.
New post, with ACHIEVE-4:
midgardfinance.com/blog/2026/10/01/weekly-insulin-onswik-awiqli/
